New medications in development for the treatment of hyperuricemia of gout

Current Opinion in Rheumatology

Volumn 27, Issue 2, 2015, Pages 164-169

  Diaz Torné, Cesar ^a   Perez Herrero, Nuria ^b   Perez Ruiz, Fernando ^c  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b UNIVERSIDAD REY JUAN CARLOS   (Spain)

^c BIOCRUCES BIZKAIA HEALTH RESEARCH INSTITUTE   (Spain)

Author keywords

arhalofenate; gout; gout suppressants; lesinurad; ulodesine; uric acid

Indexed keywords

ALLOPURINOL; ANTIGOUT AGENT; ARHALOFENATE; FEBUXOSTAT; LESINURAD; RDEA 3170; ULODESINE; UNCLASSIFIED DRUG; URATE OXIDASE; URATE TRANSPORTER; ACETAMIDE DERIVATIVE; IMINOSUGAR; PHENYLACETIC ACID DERIVATIVE; PYRIMIDINONE DERIVATIVE; THIOGLYCOLIC ACID DERIVATIVE; TRIAZOLE DERIVATIVE; URICOSURIC AGENT;

GOUT; HUMAN; HYPERURICEMIA; INTESTINAL EXCRETION; KIDNEY TUBULE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; DRUG DESIGN; MOLECULARLY TARGETED THERAPY; PROCEDURES;

ACETAMIDES; DRUG DESIGN; GOUT; GOUT SUPPRESSANTS; HUMANS; HYPERURICEMIA; IMINO FURANOSES; MOLECULAR TARGETED THERAPY; PHENYLACETATES; PYRIMIDINONES; THIOGLYCOLATES; TRIAZOLES; URICOSURIC AGENTS;

EID: 84922400298     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0000000000000146     Document Type: Review

References (19)

1. Schlesinger N, Alten RE, Bardin T, et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis 2012; 71:1839-1848.
2. Hirsch JD, Gnanasakthy A, Lale R, et al. Efficacy of Canakinumab vs. triamcinolone acetonide according to multiple gouty arthritisrelated health outcomes measures. Int J Clin Pract 2014; 68:1503-1507.
3. Schlesinger N, Mysler E, Lin H-Y, et al. Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study. Ann Rheum Dis 2011; 70:1264-1271.
4. Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006; 65:1312-1324.
5. Khanna D, Khanna PP, Fitzgerald JD, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken) 2012; 64:1447-1461.
6. French Ministry of Social Affairs and Health [online]. http://medicprix.sante. gouv.fr/medicprix/recherchePresentationInitialisee.do. [Accessed 23 November 2014]
7. Kapur S, Bonk ME. Rilonacept (arcalyst), an interleukin-1 trap for the treatment of cryopyrin-associated periodic syndromes. P T 2009; 34:138-141.
8. McGonagle D, Tan AL, Madden J, et al. Successful treatment of resistant pseudogout with anakinra. Arthritis Rheum 2008; 58:631-633.
9. Announ N, Palmer G, Guerne P-A, et al. Anakinra is a possible alternative in the treatment and prevention of acute attacks of pseudogout in end-stage renal failure. Joint Bone Spine 2009; 76:424-426.
10. Couderc M, Mathieu S, Glace B, et al. Efficacy of anakinra in articular chondrocalcinosis: report of three cases. Joint Bone Spine 2012; 79:330-331.
11. MoltóA, Ea H-K, Richette P, et al. Efficacy of anakinra for refractory acute calcium pyrophosphate crystal arthritis. Rev Rhum 2012; 79:460-463.
12. Diamantopoulos AP, Brodin C, Hetland H, et al. Interleukin 1 blockade improves signs and symptoms of chronic calcium pyrophosphate crystal arthritis resistant to treatment. J Clin Rheumatol 2012; 18:310-311.
13. Ottaviani S, Brunier L, Sibilia J, et al. Efficacy of anakinra in calcium pyrophosphate crystal-induced arthritis: a report of 16 cases and review of the literature. Joint Bone Spine 2013; 80:178-182.
14. Deppe S, Ripperger A, Weiss J, et al. Impact of genetic variability in the ABCG2 gene on ABCG2 expression, function, and interaction with AT1 receptor antagonist telmisartan. Biochem Biophys Res Commun 2014; 443:1211-1217.
15. Bassett DR, Mikkelsen WM, Buckingham RB, et al. Effects of halofenate and probenecid on serum lipids and uric acid in hyperlipidemic, hyperuricemic adults. Clin Pharmacol Ther 1977; 22:340-351.
16. Noveck RJ, Wang Z, Zongyao FA, et al. Levotofisopam has uricosuric activity and reduces serum urate levels in patients with gout. Arthitis Rheum 2012; 64:818.
17. Ahn SO, Horiba N, Ohtomo S, et al. The therapeutic efficacy of the novel uricosuric agent UR-1102 for hyperuricemia and gout. Ann Rheum Dis 2013; 72 (Suppl 2):704.
18. Lipsky PE, Calabrese LH, Kavanaugh A, et al. Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout. Arthritis Res Ther 2014; 16:R60.
19. Hershfield MS, Ganson NJ, Kelly SJ, et al. Induced and preexisting antipolyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients. Arthritis Res Ther 2014; 16:R63.